What is Pazopanib?

Pazopanib (Pazopanib) trade name is Votrient, is an anti-cancer drug. It is a potent and selective multi-target receptor tyrosine kinase inhibitor that blocks tumor growth and inhibits angiogenesis. It has been approved by many regulatory agencies around the world (including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), etc.) for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma (STS).

Pazopanib targets angiogenesis by inhibiting enzymes including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT and FGFR, thereby limiting tumor growth. Patients who need to be treated with pazopanib must obtain a doctor's prescription. The treatment phase is to continue treatment for more than 3 months. According to the solid tumor response evaluation criteria, the patient must have stable or remission disease.

PazopanibThe original drug has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be around 3,000 yuan. The price of pazopanib original drug specifications200mg*30 tablets marketed overseas may be around 1,000 RMB per box (the price may fluctuate due to exchange rates). There are also pazopanib generic drugs produced in other countries. The price of 200mg*30 tablets produced by Bangladesh pharmaceutical factory may be around 500 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.